Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4641 | oxyhydrogen Wiki | 0.50 |
| drug2981 | Placebo oral tablet Wiki | 0.09 |
| drug1775 | Hydroxychloroquine Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
This study will evaluate the efficacy and safety of Hydrogen-Oxygen Generator with Nebulizer (model AMS-H-03) developed by Shanghai Asclepius Meditech Co., Ltd. as an adjuvant therapy for the patients with COVID-19 infected pneumonia in improving the clinical symptoms and reducing the incidence of severe pneumonia, as compared with the reference device of EverFlo Oxygen Concentrator (registration certificate No.: NMPA Registration Standard: 20162542389) manufactured by Respironics, Inc. US.
Description: The time from the patient's admission to the Disease Progression to critical type，up to 2 weeks.
Measure: Recovery time Time: The day from the patient's admission to the Disease Progression to critical type，up to 2 weeks.Description: Clinical Symptom Remission was defined as: The patient's body temperature was normal for more than 72 hours (without taking antipyretics or hormones) and had no conscious dyspnea or decreased dyspnea.
Measure: Clinical Symptom Remission time Time: The day from admission to clinical remission,up to 2 weeks.Description: fever duration is the time during the patient's body temperature was abnormal。
Measure: fever duration Time: The day from the patient's body temperature was abnormal to normal,up to 2 weeks.Description: The scale consisted of 19 questions in three domains: physical, psychological and social, each with a score ranging from 1.7. Each item represented an adverse event caused by a cough. The answer was scored on a Likert 7 point scale. The higher the score, the better the health condition. The total score ranged from 7 to 21.
Measure: Leicester cough questionaire (LCQ) Time: The day from admission to clinical remission,up to 2 weeks.Description: The minimum oxygen absorption flow with 95% oxygen saturation.
Measure: minimum oxygen Time: The day from admission to clinical remission,up to 2 weeks.Description: Negative conversion rate of novel coronavirus nucleic acid in respiratory tract specimens 14 days after enrollment.
Measure: Negative conversion rate Time: the first day to the 14th days.Description: White blood cell (WBC) is a colorless, spherical and nucleated blood cell. The total number of normal adults is (4.0-10.0) x 109 / L, which can be changed in a certain range due to different time of day and the functional state of the body.
Measure: white blood cell(WBC) Time: The day of admission and clinical remission,up to 2 weeks.Description: also known as red blood cells, are often abbreviated into RBC in Chinese and English in routine tests. They are the most numerous blood cells in the blood, and also the most important medium for transporting oxygen through the blood in vertebrates. At the same time, they also have immune functions.
Measure: Red blood cells(RBC) Time: The day of admission and clinical remission,up to 2 weeks.Description: The abbreviation of hemoglobin is HGB or Hb. Hemoglobin is a special protein that transports oxygen in red blood cells. It makes the blood red. It is composed of globin and heme. Its globin part is a tetramer composed of two different pairs of globin chains (α chain and β chain).
Measure: Hemoglobin(Hb ) Time: The day of admission and clinical remission,up to 2 weeks.Description: Platelets are small pieces of cytoplasm released from the cytoplasm of mature megakaryocytes in bone marrow. Although megakaryocytes are the least in the hematopoietic cells of bone marrow, accounting for only 0.05% of the total number of bone marrow nucleated cells, the platelets produced by megakaryocytes are very important for the hemostatic function of the body.
Measure: Platelets(PLT) Time: The day of admission and clinical remission,up to 2 weeks.Description: Lymphocyte count refers to count and calculate the percentage of different types of white blood cells.
Measure: Lymphocyte count Time: The day of admission and clinical remission,up to 2 weeks.Description: Lymphocyte has the function of producing and carrying antibody and preventing virus infection. The percentage of lymphocyte was determined by routine blood test, and the normal value was 20.0% - 40.0%. The percentage of lymphocyte increased mainly in infectious diseases and decreased mainly in immune deficiency diseases.
Measure: The percentage of lymphocyte Time: The day of admission and clinical remission,up to 2 weeks.Description: The membrane of neutrophils can release an unsaturated fatty acid, arachidonic acid. Under the action of enzyme, arachidonic acid can further generate a group of paracrine hormone substances, such as thromboxane and prostaglandin, which play an obvious role in regulating the caliber and permeability of blood vessels, can also cause inflammation and pain, and affect blood coagulation.
Measure: neutrophils Time: The day of admission and clinical remission,up to 2 weeks.Description: C-reactive protein (CRP) is a kind of protein (acute protein) which rises sharply in the plasma when the body is infected or damaged by tissue. It can activate the complement and strengthen the phagocytosis of phagocytes, so as to play a role in regulating. It can clear away the pathogenic microorganism and the damaged, necrotic and apoptotic tissue cells.
Measure: C-reactive protein (CRP) Time: The day of admission and clinical remission,up to 2 weeks.Description: Myocardial enzyme is a general term for many enzymes existing in the heart, including aspartate aminotransferase (AST), lactate dehydrogenase (LD or LDH), creatine kinase (CK) and isoenzyme, a-hydroxybutyrate dehydrogenase (a-hbd), etc. during acute myocardial infarction, a variety of enzymes in the heart are released due to the necrosis of myocardial cells, so the determination of serum central muscle enzyme is useful for the diagnosis and evaluation of myocardial infarction There is a certain value in the effect of supposition
Measure: Myocardial enzyme Time: The day of admission and clinical remission,up to 2 weeks.Description: The purpose of liver function examination is to detect the liver disease, the degree of liver damage, the cause of liver disease, the prognosis and the cause of jaundice. At present, there are many kinds of clinical trials of liver function, no less than dozens. But each kind of liver function test can only detect a certain function of a certain aspect of the liver, so far, there is still no one test that can reflect all the functions of the liver.
Measure: liver function Time: The day of admission and clinical remission,up to 2 weeks.Description: Renal function refers to the function of the kidney to excrete the body's metabolic waste, maintain the stability of electrolytes such as sodium, potassium, calcium and acid-base balance. Renal function examination includes blood creatinine, blood urea nitrogen, blood and urine β 2-microglobulin, urinary albumin, urinary immunoglobulin G, urinary secretory immunoglobulin A, etc.
Measure: Renal function Time: The day of admission and clinical remission,up to 2 weeks.Description: Muscle enzyme generally refers to: phosphocreatine kinase and creatine kinase isoenzyme examination, and some glutamic oxaloacetate transaminase. It is mainly used to check common muscle diseases.
Measure: Muscle enzyme Time: The day of admission and clinical remission,up to 2 weeks.Patients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory failure at ICU admission.
Description: Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy
Measure: Days alive without organ support Time: Within 90 daysDescription: All-cause mortality 90 days after randomisation
Measure: 90-days mortality Time: 90 daysDescription: Percentage of days alive out of the hospital
Measure: Days alive out of the hospital Time: Within 90 daysDescription: Serious adverse events are defined as new episode of shock and new episodes of ischaemic events including myocardial or intestinal ischaemia or ischaemic stroke
Measure: Number of patients with one or more serious adverse events Time: Until ICU discharge, maximum 90 daysDescription: All-cause mortality 1 year after randomisation
Measure: 1-year mortality Time: 1 yearDescription: EQ-5D-5L 1-year after randomisation
Measure: Quality of life assessement using the EuroQoL EQ-5D-5L telephone interview Time: 1 yearDescription: RBANS score 1 year after randomisation at selected sites. The overall RBANS global cognition score, as well as each cognitive domain score, range from 40 to 160 with 100 ± 15 being the age-adjusted mean ± standard deviation. Higher scores indicate better performance.
Measure: Cognitive function 1-year after randomisation as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in selected sites Time: 1 yearDescription: Carbon monoxide diffusion capacity (DLCO) 1 year after randomisation at selected sites.
Measure: Carbon monoxide diffusion capacity Time: 1 yearDescription: Cost-effectiveness versus cost-minimisation analyses after completion of the trial, based on the primary outcome.
Measure: A health economic analysis Time: 90 daysPatients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory failure at ICU admission.
Description: Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy
Measure: Days alive without organ support Time: Within 90 daysDescription: All-cause mortality 90 days after randomisation
Measure: 90-days mortality Time: 90 daysDescription: Percentage of days alive out of the hospital
Measure: Days alive out of the hospital Time: Within 90 daysDescription: Serious adverse events are defined as new episode of shock and new episodes of ischaemic events including myocardial or intestinal ischaemia or ischaemic stroke
Measure: Number of patients with one or more serious adverse events Time: Until ICU discharge, maximum 90 daysDescription: All-cause mortality 1 year after randomisation
Measure: 1-year mortality Time: 1 yearDescription: EQ-5D-5L 1-year after randomisation
Measure: Quality of life assessement using the EuroQoL EQ-5D-5L telephone interview Time: 1 yearDescription: RBANS score 1 year after randomisation at selected sites. The overall RBANS global cognition score, as well as each cognitive domain score, range from 40 to 160 with 100 ± 15 being the age-adjusted mean ± standard deviation. Higher scores indicate better performance.
Measure: Cognitive function 1-year after randomisation as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in selected sites Time: 1 yearDescription: Carbon monoxide diffusion capacity (DLCO) 1 year after randomisation at selected sites.
Measure: Carbon monoxide diffusion capacity Time: 1 yearDescription: Cost-effectiveness versus cost-minimisation analyses after completion of the trial, based on the primary outcome.
Measure: A health economic analysis Time: 90 daysAt least 1 in 6 COVID-19 patients admitted to hospital to receive extra oxygen will die of complications. In patients with COVID-19, invasive treatment such as mechanical ventilation (e.g. breathing with a machine) is associated with a 50% increased risk of death. Invasive treatments use a lot of healthcare resources in intensive care units and may lead to further deaths if patients do not have access to care. The investigators aim to improve outcomes for COVID-19 patients by implementing hyperbaric oxygen therapy (HBOT). HBOT allows patients to breathe 100% oxygen in a special chamber at a pressure higher than sea level. It is approved by Health Canada for 14 conditions. HBOT is safe when administered by experienced teams. There are two main causes of death in severe COVID-19 respiratory infections: (i) a decreased diffusion of oxygen from the lungs to the blood and (ii) an increased inflammatory response (also called a "cytokine storm"). HBOT leads to increased oxygen level in blood, has strong anti-inflammatory effects, and may destroy the virus responsible for COVID-19 disease. The initial experience with HBOT and COVID-19 from China, France and the United States is promising in that it prevents further worsening of the condition and need for intensive care. The investigators propose to test the effectiveness of HBOT for COVID-19 patients who are admitted to hospital to receive extra oxygen. Using the most rigorous and innovative research methods, this Canadian-led international study will operate at 5 centers across 3 countries (Canada: Ottawa, Toronto, Edmonton; Switzerland: Geneva; UK: Rugby/London). The investigators anticipate that when treated by HBOT, COVID-19 patients needing extra oxygen to breathe will see significant health improvements as well as a decrease in complications, inflammation in the blood, need for invasive care, death, and cost of care.
Description: 7-level scale based on patient's current status and need for oxygenation, also ability to resume normal activities (at higher levels). Range is 1-7. Higher number indicates better clinical outcome.
Measure: 7-level COVID Ordinal Outcome Scale Time: Measured on Day 7Description: Measured in days
Measure: Length of hospital stay Time: Duration of study (to Day 28)Description: Number of days with oxygen supplementation
Measure: Days with oxygen supplementation Time: Duration of study (to Day 28)Description: Measured in L/min
Measure: Daily oxygen flow values required to obtain saturation values ≥90%, Time: Duration of study (to Day 28)Description: Yes/No
Measure: ICU admission Time: Duration of study (to Day 28)Description: Measured in days, if applicable
Measure: ICU length of stay Time: Duration of study (to Day 28)Description: Number of days on ventilator
Measure: Days on invasive mechanical ventilation or high flow oxygenation Time: Duration of study (to Day 28)Description: e.g. stroke, pulmonary embolism, deep vein thrombosis
Measure: Major arterial and venous thrombotic events Time: Duration of study (to Day 28)Description: Sleep Quality Scale, measured from 0 to 10. Higher number indicates worse sleep quality: 0 = "best possible sleep", 10 = "worst possible sleep". Capelleri et. al; Health and Quality of Life Outcomes 2009: 7:54
Measure: Sleep quality Time: Duration of study (to Day 28)Description: Single-Item Fatigue Report Mark, measured from 1 to 10. Higher number indicates worse fatigue: 1 = "not at all", 10 = "extremely". van Hooff et al; J Occup Health 2007; 49:224-234.
Measure: Fatigue Time: Duration of study (to Day 28)Description: Same scale as the primary outcome; different timing as a secondary outcome. Range is 1-7. Higher number indicates better clinical outcome.
Measure: 7-level COVID Ordinal Outcome Scale Time: Measured on Day 28Description: Number of deaths
Measure: Mortality Time: Duration of study (to Day 28)Description: Number of adverse events
Measure: Incidence of any adverse events related to HBOT Time: Duration of study (to Day 28)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports